VCIM
BBIO icon

Velan Capital Investment Management’s BridgeBio Pharma BBIO Stock Holding History

Velan Capital Investment Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,125
Closed -$19K – 24
2021
Q4 		$19K Buy
+1,125
New +$47.6K 0.01% 26

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Velan Capital Investment Management's BBIO Position: Q1 2022 in Review

Velan Capital Investment Management sold out of BridgeBio Pharma (BBIO) in Q1 2022, closing a stake of 1,125 shares — an estimated $19K sold.

Velan Capital Investment Management first reported a position in BBIO in Q4 2021 and held it in 1 quarter. The position peaked at $19K in Q4 2021. 178 funds tracked by Wall St. Rank hold BBIO as of Q1 2022.

  • Velan Capital Investment Management reported no remaining BridgeBio Pharma position as of Q1 2022 after selling out during the quarter.
  • Velan Capital Investment Management sold 1,125 BridgeBio Pharma shares in Q1 2022, an estimated $19K.
  • Velan Capital Investment Management first reported a position in BridgeBio Pharma in Q4 2021 and held it in 1 quarter.
  • Velan Capital Investment Management's BridgeBio Pharma position peaked at $19K in Q4 2021.
  • 178 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2022.

Based on Velan Capital Investment Management's 13F filing for Q1 2022, filed 16 May 2022.